Monalisa Ultra — Hy-BRID HA Filler for Jawline, Nose & Chin Sculpting (900µm)

Monalisa Ultra is GENOSS’s highest-density variant — 24 mg/mL cross-linked HA + 0.3% lidocaine with the largest particle size (900µm) in the Monalisa range. Engineered for deep subcutaneous placement targeting jawline contouring, non-surgical rhinoplasty, chin augmentation, and facial volume loss restoration via Hy-BRID technology.

Monalisa Ultra with Lidocaine is manufactured by GENOSS Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2007. The product is part of the Monalisa dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE 2195 · KGMP · ISO 13485 · ISO 9001.

Monalisa Ultra with Lidocaine contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using GENOSS Co. Ltd.’s Hy-BRID Cross-Linking Technology (900µm particles) technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per GENOSS Co. Ltd.’s clinical data, Monalisa Ultra with Lidocaine delivers Up to 6 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Deep subcutaneous placement typically delivers the longer end of the duration range.

Monalisa Ultra with Lidocaine is engineered for deep subcutaneous placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Monalisa Ultra with Lidocaine regulatory status: KFDA registered · CE 2195 · KGMP · ISO 13485 · ISO 9001. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Monalisa Ultra with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Monalisa Ultra with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Monalisa Ultra with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

GENOSS’s Monalisa range maintains a constant 24 mg/mL HA concentration across all four variants (Soft, Mild, Hard, Ultra) — the differentiation comes from particle size (200µm → 400µm → 600µm → 900µm) and cross-linking density via Hy-BRID technology. Larger particles in Ultra produce a firmer, more cohesive gel for deep subcutaneous placement; smaller particles in Soft produce a softer gel for superficial work. This approach lets practitioners maintain HA-equivalent dosing across variants while selecting density by tissue depth.